Ex-Tokai CEO follows tau pathway to Alzheimer's upstart

Last week Cambridge, MA-based Tokai Pharmaceuticals revealed that Martin Williams would leave the company without explaining where he was going, Mass High Tech reported. After leaving the cancer drug developer, Williams now tells the Boston tech pub that he has taken the top job at Yuma Pharmaceuticals, which is researching small molecule drugs that target the tau pathway to combat Alzheimer's disease and other neuroscience indications. Williams is a former business chief for Dicerna and Synta. Article